Drug General Information (ID: DDILDB3X8C)
Drug Name			Ipilimumab		Drug Info		Vemurafenib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Multikinase Inhibitors

Mechanism of Ipilimumab-Vemurafenib Interaction (Severity Level: Moderate)
Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Ipilimumab				Vemurafenib
Mechanism		Hepatotoxicity				Hepatotoxicity
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage.
Mechanism Description		Increased risk of hepatotoxicity by the combination of Ipilimumab and Vemurafenib

Recommended Action
Management		The safety and effectiveness of vemurafenib in combination with ipilimumab have not been established. Liver transaminases, alkaline phosphatase, and bilirubin should be monitored prior to initiation of vemurafenib treatment and monthly during treatment, or as clinically indicated. Laboratory abnormalities should be managed with dosage reduction, treatment interruption, or treatment discontinuation in accordance with the product labeling.

References
1	Product Information. Yervoy (ipilimumab). Bristol-Myers Squibb, Princeton, NJ.
2	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.